About Beijing Gene+ Technology

Beijing Gene provides next-generation sequencing (NGS) technology for comprehensive cancer gene testing, enabling early detection and personalized treatment options. Their services address the need for precise cancer prevention and monitoring through advanced genetic analysis and tailored health assessments.

```xml <problem> Current cancer gene testing methods often lack the sensitivity for early detection and may not provide comprehensive information for personalized treatment strategies. This can lead to delayed diagnoses and suboptimal treatment plans, impacting patient outcomes. </problem> <solution> Beijing Gene provides next-generation sequencing (NGS)-based cancer gene testing services designed for early detection, personalized treatment, and comprehensive disease monitoring. Their services utilize advanced genetic analysis to identify tumor-specific mutations and assess an individual's risk profile. By offering a range of tests, including early screening, precision medication guidance, and full-disease course monitoring, Beijing Gene enables clinicians to make informed decisions throughout the cancer care continuum. The company leverages an intelligent platform to streamline the NGS workflow, from sample processing to data analysis and reporting. </solution> <features> - Tumor gene detection for precision medication guidance - Full-disease course monitoring to track treatment response and disease progression - Early screening and diagnosis tests for multiple cancer types - NGS platform for pathogen gene detection - NGS-based Minimum Residual Disease (MRD) assays for post-treatment monitoring - Gene⁺Seq-100 gene sequencer - NGS platform in-hospital integrated solution </features> <target_audience> Beijing Gene's primary customers include hospitals, oncology clinics, research institutions, and pharmaceutical companies seeking advanced NGS-based solutions for cancer management. </target_audience> ```

What does Beijing Gene+ Technology do?

Where is Beijing Gene+ Technology located?

Beijing Gene+ Technology is based in Changping, China.

When was Beijing Gene+ Technology founded?

Beijing Gene+ Technology was founded in 2015.

Location

Changping, China

Founded

2015

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Beijing Gene+ Technology

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

geneplus.org.cn

Founded 2015 – Changping, China

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Current cancer gene testing methods often lack the sensitivity for early detection and may not provide comprehensive information for personalized treatment strategies. This can lead to delayed diagnoses and suboptimal treatment plans, impacting patient outcomes.

Solution

Beijing Gene provides next-generation sequencing (NGS)-based cancer gene testing services designed for early detection, personalized treatment, and comprehensive disease monitoring. Their services utilize advanced genetic analysis to identify tumor-specific mutations and assess an individual's risk profile. By offering a range of tests, including early screening, precision medication guidance, and full-disease course monitoring, Beijing Gene enables clinicians to make informed decisions throughout the cancer care continuum. The company leverages an intelligent platform to streamline the NGS workflow, from sample processing to data analysis and reporting.

Features

Tumor gene detection for precision medication guidance

Full-disease course monitoring to track treatment response and disease progression

Early screening and diagnosis tests for multiple cancer types

NGS platform for pathogen gene detection

NGS-based Minimum Residual Disease (MRD) assays for post-treatment monitoring

Gene⁺Seq-100 gene sequencer

NGS platform in-hospital integrated solution

Target Audience

Beijing Gene's primary customers include hospitals, oncology clinics, research institutions, and pharmaceutical companies seeking advanced NGS-based solutions for cancer management.